Abstract
Participants at the February 2011 meeting at the U.S. National Institutes of Health on Epstein-Barr virus (EBV) vaccine research recommend that future clinical trials have two goals: prevention of infectious mononucleosis and EBV-associated cancers, facilitated by identification of disease-predictive surrogate markers.
Original language | English (US) |
---|---|
Article number | 107fs7 |
Journal | Science Translational Medicine |
Volume | 3 |
Issue number | 107 |
DOIs | |
State | Published - Nov 2 2011 |
Externally published | Yes |
ASJC Scopus subject areas
- Medicine(all)